<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552106</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol_V1.2_KUDZU</org_study_id>
    <nct_id>NCT04552106</nct_id>
  </id_info>
  <brief_title>Dose Finding Evaluation of Kudzu Root Extract in Women With Menopause Symptoms</brief_title>
  <acronym>KUDZU-01</acronym>
  <official_title>An Open-label, Single-center, Randomized, Exploratory, Dose-finding Study to Evaluate Short Term Treatment With Different Doses of Oral Powdered Kudzu Root Extract in Women With at Least Mild Menopause Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Bioscience A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate effects of daily intake of Nordic Kudzu for 28 days in&#xD;
      5 groups of 10 menopausal women with symptoms. Groups:1) 3 capsules x3/day, 2) 3 capsules&#xD;
      x2/day, 3) 2 capsules x3/day, 4) 2 capsules x2/day, 5) 3 capsules x1/day. Each capsule equal&#xD;
      1.26 g kudzu root extract. Outcome measures: Serum and urine levels of biochemical marker of&#xD;
      bone-degradation, CTX-I, and symptoms of menopause using the Meopause Rating Scale (MRS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Actual">November 15, 2018</completion_date>
  <primary_completion_date type="Actual">November 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Unblinded, single-center, randomized, exploratory, dose-finding study. 1:1:1:1:1 randomisation to 5 groups of different doses for 28 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menopause Rating Scale (MRS)</measure>
    <time_frame>28 days</time_frame>
    <description>Questionaire. 11 likert scales 0-4. Total score ranges: 0-44 (0 indicating no symptoms, 44 indicating max symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum CTX-I</measure>
    <time_frame>28 days</time_frame>
    <description>Blood based biomarker of bone resorption</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine CTX-I</measure>
    <time_frame>28 days</time_frame>
    <description>Urine based biomarker of bone resorption</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>3 caps x3/day</intervention_name>
    <description>3 capsules 3 times daily for 28 days</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>3 caps x2/day</intervention_name>
    <description>3 capsules 2 times daily for 28 days</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>2 caps x3/day</intervention_name>
    <description>2 capsules 3 times daily for 28 days</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>2 caps x2/day</intervention_name>
    <description>2 capsules 2 times daily for 28 days</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>3 caps x1/day</intervention_name>
    <description>3 capsules 1 times daily for 28 days</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Signed and dated informed consent&#xD;
&#xD;
          2. Women in the age between 45 and 60 years considered late peri- (defined as having had&#xD;
             a menstrual period more than 3 months ago but less than 12 months ago) or&#xD;
             postmenopausal (defined as at least 12 consecutive months without any menstrual flow)&#xD;
             at the time of screening&#xD;
&#xD;
          3. Menopause symptoms, defined as a score of at least 5 in the Menopausal Rating Scale&#xD;
             (MRS) at screening&#xD;
&#xD;
          4. Body Mass Index between 18 and 40 kg/m2 at the time of screening&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Allergy/hypersensitivity/intolerance to any components in the Kudzu herbal extract&#xD;
             powder capsules&#xD;
&#xD;
          2. Past or present significant co-morbidity including, but not limited to: Uncontrolled,&#xD;
             severe renal, hepatic, cardiovascular, hematologic, gastrointestinal, metabolic,&#xD;
             endocrine, pulmonary, cardiac or neurologic disease&#xD;
&#xD;
          3. History of breast cancer or other malignancy, except adequately treated basal cell or&#xD;
             squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ&#xD;
&#xD;
          4. Known history of clinically significant thromboembolism&#xD;
&#xD;
          5. Current alcohol abuse&#xD;
&#xD;
          6. Pregnancy, determined by positive serum human chorionic gonadotropin (hCG) test prior&#xD;
             to randomization, except for women considered postmenopausal&#xD;
&#xD;
          7. Breastfeeding women&#xD;
&#xD;
          8. Participation in a study trial with any investigational new drug or food supplement&#xD;
             within 3 months prior to the start of the study&#xD;
&#xD;
          9. Clinically significant ECG abnormalities, as judged by the investigator&#xD;
&#xD;
         10. Clinically significant biochemistry abnormalities including but not limited to ALT or&#xD;
             AST &gt;2.5 x ULN or other clinically significant liver function parameters, as judged by&#xD;
             the investigator&#xD;
&#xD;
         11. Investigator considering the subject inappropriate for inclusion in the study based on&#xD;
             medical interview and/or physical examination&#xD;
&#xD;
         12. Use of local or systemic conventional hormone therapy regardless of indication or&#xD;
             alternative medication including dietary supplements for the treatment of menopausal&#xD;
             symptoms within 28 days prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning B Nielsen, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanos Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanos Clinic</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

